Hoppa till innehållet
Zinzino group revenue increased with a total of 35 %, compared with the previous year.
The revenue in April for Zinzino's sales markets increased by 34 % and amounted to SEK 155.7 (116.0) million. Faun Pharma's external sales increased by 54 % and amounted to SEK 8.0 (5.2) million. Overall, the Group increased revenues by 35 % to SEK 163.7 (121.2) million compared with the previous year.
Accumulated revenue for January - April 2024 increased by 20 % to SEK 618.2 (514.9) million.
Revenues were distributed as follows:
Regions,MSEK 24 23 Change YTD YTD 2023 Change
-Apr -Apr 2024
The Nordics 24.7 21.5 15% 92.8 95,0 -2%
Central 44.9 29.3 53% 164.4 120.2 37%
Europe
East Europe 31.1 30.6 2% 124.9 123.1 1%
South & West 25.5 15.6 63% 96.1 64.7 49%
Europe
The Baltics 8.1 7,0 16% 32,0 28.1 14%
North 15.0 5.8 159% 50.4 25.4 98%
America
Asia-Pacific 5.3 5.2 2% 17.6 20.8 -15%
Africa 1.1 1,0 4.4 4.8 -8%
10%
Zinzino 155.7 116.0 34% 582.6 482.1 21%
Faun Pharma 8,0 5.2 54% 35.6 32.8 9%
Zinzino 163.7 121.2 35% 618.2 514.9 20%
Group
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Certified Adviser: Carnegie Investment Bank AB (publ)